A preprint article posted on September 11 by medRxiv detailed results of a study that showed that vaccine-generated mpox antibodies largely waned 6 to 12 months after administration of Jynneos, developed in 2019 by Bavarian Nordic (BVNRY), CIDRAP reported yesterday. Bavarian Nordic and Emergent BioSolutions (EBS) are the makers of the only two vaccines that the U.S. CDC currently recommends for mpox. In late 2023, GeoVax Labs (GOVX) announced that it had amended a previously executed Patent and Biological Materials License Agreement with the National Institute of Allergy and Infectious Diseases to expand GeoVax’s commercial license to include mpox and smallpox as additional indications.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BVNRY:
- Bavarian Nordic announces commercial availability of VAXCHORA in Canada
- Biotech Alert: Searches spiking for these stocks today
- Applied Materials, H&R Block report quarterly beats: Morning Buzz
- Logistical issues with vaccine pose risk to mpox response, FT reports
- Bavarian Nordic applies to EMA to use mpox vaccine in adolescents, FT reports